Specifically, they discovered potential ESCC subset-specific diagnostic markers: EYA2 and FOXA1 for subtype I and KRT14 and LAMC2 for subtype II, which may help guide ESCC clinical treatment. Here, EYA2 is linked to esophageal squamous cell carcinoma.